Shuttle Pharmaceuticals Holdings (SHPH) Change in Accured Expenses (2021 - 2026)
Shuttle Pharmaceuticals Holdings (SHPH) posted quarterly Change in Accured Expenses of $335951.0 for Q1 2026, up 322.49% year-over-year from $79517.0 in Q1 2025, and up 174.11% quarter-over-quarter from -$453303.0 in Q4 2025.
Shuttle Pharmaceuticals Holdings (SHPH) Change in Accured Expenses (2021 - 2026) Analysis & Trends
Shuttle Pharmaceuticals Holdings' Change in Accured Expenses history runs 6 years deep, the most recent figure standing at $335951.0 for Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 322.49% year-over-year to $335951.0; the TTM figure through Mar 2026 stood at $679428.0 (up 2075.0% YoY), while the FY2025 annual figure was $422994.0, up 2909.47% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at $335951.0, up from -$453303.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $1.0 million in Q3 2024, with the low at -$1.1 million in Q4 2024.
- The 5-year median for Change in Accured Expenses is $9592.0 (2022), against an average of $27733.0.
- Peak annual rise in Change in Accured Expenses reached 8627.57% in 2024, while the deepest fall reached 2389.59% in 2024.
- Shuttle Pharmaceuticals Holdings' Change in Accured Expenses stood at $9592.0 in 2022, then soared by 392.06% to $47198.0 in 2023, then slumped by 2389.59% to -$1.1 million in 2024, then soared by 58.05% to -$453303.0 in 2025, then soared by 174.11% to $335951.0 in 2026.
- Business Quant data shows SHPH's Change in Accured Expenses at $335951.0 in Q1 2026, -$453303.0 in Q4 2025, and $331198.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Shuttle Pharmaceuticals Holdings | 1.87 Mn | 1.87 Mn | - | 335,951.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 335,951.00 |
| Mar 31, 2026 | 335,951.00 |
| Dec 31, 2025 | -453,303.00 |
| Dec 31, 2025 | -453,303.00 |
| Sep 30, 2025 | 331,198.00 |
| Sep 30, 2025 | 331,198.00 |
| Jun 30, 2025 | 465,582.00 |
| Jun 30, 2025 | 465,582.00 |
| Mar 31, 2025 | 79,517.00 |
| Mar 31, 2025 | 79,517.00 |
| Dec 31, 2024 | -1.08 Mn |
| Dec 31, 2024 | -1.08 Mn |
| Sep 30, 2024 | 1.05 Mn |
| Sep 30, 2024 | 1.05 Mn |
| Jun 30, 2024 | -12,778.00 |
| Jun 30, 2024 | -12,778.00 |
| Mar 31, 2024 | 33,223.00 |
| Mar 31, 2024 | 33,223.00 |
| Dec 31, 2023 | 47,198.00 |
| Dec 31, 2023 | 47,198.00 |